Home Actualité internationale CM – Sage (SAGE) stock drops after disappointing secondary data from zuranolone in a depression study
Actualité internationale

CM – Sage (SAGE) stock drops after disappointing secondary data from zuranolone in a depression study

Sage Therapeutics (SAGE) and Biogen (BIIB) announce that the Phase 3 WATERFALL study in patients with major depressive disorder (MDD) has achieved its primary endpoint of ...

A LIRE AUSSI ...

Pour la première fois, il existe une pilule contre la dépression post-partum

Because the pill works faster than other antidepressants and is taken for...

CM – Ping Identity Drops 6% in Stock Offering

Ping Identity Holding (PING) is launching a public follow-up offer of 6...

[quads id=1]